Charles Newton
Finanzdirektor/CFO bei LYELL IMMUNOPHARMA, INC.
Vermögen: 119 883 $ am 31.05.2024
Aktive Positionen von Charles Newton
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
LYELL IMMUNOPHARMA, INC. | Finanzdirektor/CFO | 01.02.2021 | - |
COHERUS BIOSCIENCES, INC. | Direktor/Vorstandsmitglied | 05.05.2022 | - |
Independent Dir/Board Member | 05.05.2022 | - | |
2SEVENTY BIO, INC. | Direktor/Vorstandsmitglied | 20.03.2024 | - |
Independent Dir/Board Member | 20.03.2024 | - |
Karriereverlauf von Charles Newton
Ehemalige bekannte Positionen von Charles Newton
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Carmot Therapeutics, Inc.
Carmot Therapeutics, Inc. BiotechnologyHealth Technology Carmot Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of therapeutics for metabolic diseases, cancer, and inflammation. Its pipeline includes CT-388, CT-996, and CT-868. The CT-388 refers to treatment taken once-weekly subcutaneous injectable for obesity and type 2 diabetes (T2D). The CT-996 comprises of once-daily oral treatment for obesity and T2D. The CT-868 consists of once-daily subcutaneous injectable for treatment of type 1 diabetes (T1D) patients with overweight or obesity. The company was founded in 2008 and is headquartered in Berkeley, CA. | Direktor/Vorstandsmitglied | 19.07.2023 | 01.01.2024 |
Independent Dir/Board Member | 19.07.2023 | 01.01.2024 | |
Credit Suisse Group AG /US/
Credit Suisse Group AG /US/ Financial ConglomeratesFinance Credit Suisse Group AG /US/ engages in the provision of financial solutions. It offers services for private banking, investment banking, and asset management. The company is headquartered in New York, NY. | Vorstandsvorsitzender | 01.09.2010 | 01.11.2015 |
MORGAN STANLEY | Corporate Officer/Principal | 01.06.1996 | 01.09.2010 |
BofA Securities, Inc.
BofA Securities, Inc. Investment Banks/BrokersFinance BofA Securities, Inc. is a registered broker-dealer subsidiary of NB Holdings Corp., ultimately held by Bank of America Corp. (NYSE: BAC). Headquartered in New York, the firm was founded in 2015 and offers trade execution, trading or brokerage services to institutional clients. | Corporate Officer/Principal | - | - |
Ausbildung von Charles Newton
Tuck School of Business at Dartmouth | Masters Business Admin |
Miami University | Undergraduate Degree |
Statistik
International
Vereinigte Staaten | 10 |
Operativ
Director/Board Member | 3 |
Independent Dir/Board Member | 3 |
Corporate Officer/Principal | 2 |
Sektoral
Health Technology | 5 |
Finance | 4 |
Consumer Services | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 4 |
---|---|
LYELL IMMUNOPHARMA, INC. | Health Technology |
COHERUS BIOSCIENCES, INC. | Health Technology |
MORGAN STANLEY | Finance |
2SEVENTY BIO, INC. | Health Technology |
Private Unternehmen | 3 |
---|---|
Credit Suisse Group AG /US/
Credit Suisse Group AG /US/ Financial ConglomeratesFinance Credit Suisse Group AG /US/ engages in the provision of financial solutions. It offers services for private banking, investment banking, and asset management. The company is headquartered in New York, NY. | Finance |
BofA Securities, Inc.
BofA Securities, Inc. Investment Banks/BrokersFinance BofA Securities, Inc. is a registered broker-dealer subsidiary of NB Holdings Corp., ultimately held by Bank of America Corp. (NYSE: BAC). Headquartered in New York, the firm was founded in 2015 and offers trade execution, trading or brokerage services to institutional clients. | Finance |
Carmot Therapeutics, Inc.
Carmot Therapeutics, Inc. BiotechnologyHealth Technology Carmot Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of therapeutics for metabolic diseases, cancer, and inflammation. Its pipeline includes CT-388, CT-996, and CT-868. The CT-388 refers to treatment taken once-weekly subcutaneous injectable for obesity and type 2 diabetes (T2D). The CT-996 comprises of once-daily oral treatment for obesity and T2D. The CT-868 consists of once-daily subcutaneous injectable for treatment of type 1 diabetes (T1D) patients with overweight or obesity. The company was founded in 2008 and is headquartered in Berkeley, CA. | Health Technology |
- Börse
- Insiders
- Charles Newton
- Erfahrung